Wang L J, Chen Y, Xiang M, Yang X F, Chen S N
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Medical Research Center for Hematological Diseases, Suzhou 215006, China.
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):132-136. doi: 10.3760/cma.j.issn.0253-2727.2023.02.008.
To assess the clinical characteristics and prognosis of patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia (T-ALL) . The clinical data of 19 SIL-TAL1-positive T-ALL patients admitted to the First Affiliated Hospital of Soochow University between January 2014 and February 2022 were retrospectively computed and contrasted with SIL-TAL1-negative T-ALL patients. The median age of the 19 SIL-TAL1-positive T-ALL patients was 15 (7 to 41 years) , including 16 males (84.2%) . SIL-TAL1-positive T-ALL patients had younger age, higher WBC, and hemoglobin compared with SIL-TAL1-negative T-ALL patients. There was no discrepancy in gender distribution, PLT, chromosome abnormality distribution, immunophenotyping, and complete remission (CR) rate. The 3-year overall survival (OS) was 60.9% and 74.4%, respectively (=2.070, =0.071) . The 3-year relapse-free survival (RFS) was 49.2% and 70.6%, respectively (=2.275, =0.040) . The 3-year RFS rate of SIL-TAL1-positive T-ALL patients was considerably lower than SIL-TAL1-negative T-ALL patients. SIL-TAL1-positive T-ALL patients were connected to younger age, higher WBC, higher HGB, and poor outcome.
评估SIL-TAL1阳性T细胞急性淋巴细胞白血病（T-ALL）患者的临床特征及预后。回顾性分析2014年1月至2022年2月期间苏州大学附属第一医院收治的19例SIL-TAL1阳性T-ALL患者的临床资料，并与SIL-TAL1阴性T-ALL患者进行对比。19例SIL-TAL1阳性T-ALL患者的中位年龄为15岁（7至41岁），其中男性16例（84.2%）。与SIL-TAL1阴性T-ALL患者相比，SIL-TAL1阳性T-ALL患者年龄更小，白细胞计数和血红蛋白水平更高。性别分布、血小板计数、染色体异常分布、免疫表型及完全缓解（CR）率方面无差异。3年总生存率（OS）分别为60.9%和74.4%（=2.070，=0.071）。3年无复发生存率（RFS）分别为49.2%和70.6%（=2.275，=0.040）。SIL-TAL1阳性T-ALL患者的3年RFS率显著低于SIL-TAL1阴性T-ALL患者。SIL-TAL1阳性T-ALL患者与年龄较小、白细胞计数较高、血红蛋白水平较高及预后较差相关。
